TNFRSF12A and neoplasm: Preclinical and Phase I clinical trials have tested the efficacy of agonistic anti-Fn14 or antagonistic anti-TWEAK antibodies for multiple tumor subtypes, including breast carcinoma and melanoma [34–37].